Cafepharma Today

June 2 2025 - Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Sanofi expands rare immunology portfolio with Blueprint buyout
Moderna's next-gen COVID shot gets FDA backing with some limitations
BioNTech flips its cancer bispecific to BMS for a big profit
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

J&J sees device growth through new products, emerging markets
Yahoo/Reuters
Thursday, May 22, 2014 - 9:49am
tags:
JNJ, devices, emerging markets
Roche Says Authorities Visited Office in China’s Hangzhou
Bloomberg
Thursday, May 22, 2014 - 8:42am
tags:
China, Roche
Report: Deals in the medical device sector rose 200% in Q1
Mass Device
Thursday, May 22, 2014 - 8:41am
tags:
devices, M&A
AstraZeneca shareholders disagree on Pfizer strategy, NY Times reports
The Fly on the Wall
Thursday, May 22, 2014 - 8:40am
tags:
AstraZeneca, Pfizer, M&A
StemCells advances HuCNS-SC clinical trial to final cohort
The Fly on the Wall
Thursday, May 22, 2014 - 8:39am
tags:
StemCells, HuCNS-SC, clinical trials, age-related macular degeneration
The Zacks Analyst Blog Highlights: Incyte, Celldex, Bristol-Myers, AstraZeneca and Halozyme
Yahoo/Zacks.com
Thursday, May 22, 2014 - 8:36am
tags:
Incyte, Celldex, Bristol-Myers Squibb, AstraZeneca, Halozyme
New Report Ranks 22 Drug Companies Based On R&D
Forbes
Thursday, May 22, 2014 - 8:34am
tags:
R&D
Making The Call: Vertex's Cystic Fibrosis Trials Will Succeed. Here's Why.
TheStreet.com
Thursday, May 22, 2014 - 8:33am
tags:
cystic fibrosis, Vertex Pharmaceuticals, Kalydeco
Isis Pharma's experimental blood thinner succeeds in mid-stage trial
Yahoo/Reuters
Thursday, May 22, 2014 - 8:32am
tags:
Isis Pharmaceuticals, bloodthinners, ISIS-FXIRx
All Is Not Lost: AstraZeneca plc Has Less Than 48hrs To Cut A Deal With Pfizer
Motley Fool
Thursday, May 22, 2014 - 8:30am
tags:
AstraZeneca, Pfizer, M&A
Acura Pharma announces settlement of patent litigation with Sandoz
The Fly on the Wall
Thursday, May 22, 2014 - 8:28am
tags:
Sandoz, Novartis, Acura Pharmaceuticals, patents, Aversion, Oxceta
Pfizer, BioRestorative Therapies sign research agreement
The Fly on the Wall
Thursday, May 22, 2014 - 8:25am
tags:
Pfizer, BioRestorative Therapies, brown adipose tissue, R&D
Myriad Genetics Unveils Positive Prolaris Data
Yahoo/Zacks.com
Wednesday, May 21, 2014 - 4:13pm
tags:
Myriad Genetics, Prolaris, prostate cancer
[video]Can Abbott Laboratories Breathe Life into This Struggling Business?
Motley Fool
Wednesday, May 21, 2014 - 3:37pm
tags:
Abbott Labs, M&A, CFR
Alnylam announces publication of pre-clinical results with ALN-AS1
The Fly on the Wall
Wednesday, May 21, 2014 - 11:23am
tags:
Alnylam, ALN-AS1, hepatic porphyrias
Stryker must face class action employment claims
Mass Device
Wednesday, May 21, 2014 - 11:20am
tags:
devices, employment litigation, Stryker
3 Key Takeaways From Medtronic’s Earnings
Motley Fool
Wednesday, May 21, 2014 - 11:18am
tags:
Medtronic, earnings, devices
Merck says Zontivity approved for reduction of thrombotic cardiovascular events
The Fly on the Wall
Wednesday, May 21, 2014 - 11:16am
tags:
Merck, thrombotic cardiovascular events, Zontivity, FDA
Takeda’s Bowel Disease Drug Approved by U.S. Regulators
Bloomberg
Wednesday, May 21, 2014 - 10:26am
tags:
Takeda, FDA, Entyvio, vedolizumab, ulcerative colitis, Crohn's Disease
Valeant’s Pursuit of Allergan: Go Big or Go Home
Motley Fool
Wednesday, May 21, 2014 - 10:18am
tags:
Allergan, Valeant Pharmaceuticals, M&A

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.